Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366167149> ?p ?o ?g. }
- W4366167149 endingPage "110669" @default.
- W4366167149 startingPage "110669" @default.
- W4366167149 abstract "Treatment of people with type 2 diabetes mellitus (T2D) and obesity should include glycemic control and sustained weight loss. However, organ protection and/or risk reduction for co-morbidities have also emerged as important goals. Here, we define this combined treatment approach as 'weight loss plus' and describe it as a metabolic concept where prolonged periods of energy consumption is central to outcomes. We suggest there are currently two drug classes - sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 (GLP-1)-glucagon dual agonists - that can facilitate this 'weight loss plus' approach. We describe evidence supporting that both classes address the underlying pathophysiology of T2D and facilitate normalization of metabolism through increased periods with a catabolic type of energy consumption, which effect other organ systems and may facilitate long-term cardio-renal benefits. These benefits have been demonstrated in trials of SGLT2is, and appear, to some degree, to be independent of glycemia and substantial weight loss. The combined effect of caloric restriction and metabolic correction facilitated by SGLT2i and GLP-1-glucagon dual agonists can be conceptualized as mimicking dietary restriction and physical activity, a phenomenon not previously observed with drugs whose benefits predominantly arise from absolute weight loss, and which may be key to achieving a 'weight loss plus' approach to treatment." @default.
- W4366167149 created "2023-04-19" @default.
- W4366167149 creator A5018267559 @default.
- W4366167149 creator A5034677869 @default.
- W4366167149 creator A5041155318 @default.
- W4366167149 creator A5041913215 @default.
- W4366167149 creator A5047880468 @default.
- W4366167149 date "2023-05-01" @default.
- W4366167149 modified "2023-09-25" @default.
- W4366167149 title "Perspectives in weight control in diabetes – SGLT2 inhibitors and GLP-1–glucagon dual agonism" @default.
- W4366167149 cites W1523363225 @default.
- W4366167149 cites W1798757189 @default.
- W4366167149 cites W1969335462 @default.
- W4366167149 cites W1991988767 @default.
- W4366167149 cites W2020982355 @default.
- W4366167149 cites W2021517048 @default.
- W4366167149 cites W2025389226 @default.
- W4366167149 cites W2038034590 @default.
- W4366167149 cites W2043072682 @default.
- W4366167149 cites W2089342771 @default.
- W4366167149 cites W2108940969 @default.
- W4366167149 cites W2110067540 @default.
- W4366167149 cites W2112117255 @default.
- W4366167149 cites W2121227134 @default.
- W4366167149 cites W2126177048 @default.
- W4366167149 cites W2146264128 @default.
- W4366167149 cites W2155186909 @default.
- W4366167149 cites W2157689819 @default.
- W4366167149 cites W2166613497 @default.
- W4366167149 cites W2167245776 @default.
- W4366167149 cites W2341611738 @default.
- W4366167149 cites W2399261310 @default.
- W4366167149 cites W2424539745 @default.
- W4366167149 cites W2575018533 @default.
- W4366167149 cites W2591832038 @default.
- W4366167149 cites W2614137535 @default.
- W4366167149 cites W2626446274 @default.
- W4366167149 cites W2634393565 @default.
- W4366167149 cites W2734724639 @default.
- W4366167149 cites W2759143872 @default.
- W4366167149 cites W2774108532 @default.
- W4366167149 cites W2785119187 @default.
- W4366167149 cites W2800926943 @default.
- W4366167149 cites W2808958607 @default.
- W4366167149 cites W2900413769 @default.
- W4366167149 cites W2939222610 @default.
- W4366167149 cites W2974260792 @default.
- W4366167149 cites W2981305821 @default.
- W4366167149 cites W2982363774 @default.
- W4366167149 cites W3016191918 @default.
- W4366167149 cites W3027852565 @default.
- W4366167149 cites W3043378534 @default.
- W4366167149 cites W3081830235 @default.
- W4366167149 cites W3088173406 @default.
- W4366167149 cites W3114776109 @default.
- W4366167149 cites W3133746780 @default.
- W4366167149 cites W3155173216 @default.
- W4366167149 cites W3160773731 @default.
- W4366167149 cites W3164219268 @default.
- W4366167149 cites W3164445252 @default.
- W4366167149 cites W3176790398 @default.
- W4366167149 cites W3183817162 @default.
- W4366167149 cites W3193297191 @default.
- W4366167149 cites W3196916730 @default.
- W4366167149 cites W3202519848 @default.
- W4366167149 cites W3202575491 @default.
- W4366167149 cites W4210660034 @default.
- W4366167149 cites W4221127517 @default.
- W4366167149 cites W4223420336 @default.
- W4366167149 cites W4225098447 @default.
- W4366167149 cites W4226356934 @default.
- W4366167149 cites W4283155595 @default.
- W4366167149 cites W4287832822 @default.
- W4366167149 cites W4293194528 @default.
- W4366167149 cites W4297021616 @default.
- W4366167149 cites W4308183941 @default.
- W4366167149 cites W4311182596 @default.
- W4366167149 cites W4311264067 @default.
- W4366167149 cites W4313650619 @default.
- W4366167149 doi "https://doi.org/10.1016/j.diabres.2023.110669" @default.
- W4366167149 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37075928" @default.
- W4366167149 hasPublicationYear "2023" @default.
- W4366167149 type Work @default.
- W4366167149 citedByCount "0" @default.
- W4366167149 crossrefType "journal-article" @default.
- W4366167149 hasAuthorship W4366167149A5018267559 @default.
- W4366167149 hasAuthorship W4366167149A5034677869 @default.
- W4366167149 hasAuthorship W4366167149A5041155318 @default.
- W4366167149 hasAuthorship W4366167149A5041913215 @default.
- W4366167149 hasAuthorship W4366167149A5047880468 @default.
- W4366167149 hasBestOaLocation W43661671491 @default.
- W4366167149 hasConcept C126322002 @default.
- W4366167149 hasConcept C134018914 @default.
- W4366167149 hasConcept C2776398474 @default.
- W4366167149 hasConcept C2777180221 @default.
- W4366167149 hasConcept C2778563252 @default.
- W4366167149 hasConcept C2779306644 @default.
- W4366167149 hasConcept C2780473172 @default.